AZD9574
Sponsors
AstraZeneca AB, AstraZeneca
Conditions
Advanced Solid MalignanciesBRCA2BRCA2mHER2 activating mutationIDH-mutant recurrent gliomaMetastatic Prostate CancerModule 1: advanced/relapsed ovarianModule 2: IDH-mutant glioma
Phase 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RecruitingNCT05417594
Start: 2022-06-24End: 2028-02-07Target: 695Updated: 2026-08-12
A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic Solid Malignancies.
RecruitingCTIS2022-502759-70-01
Start: 2024-02-22Target: 97Updated: 2025-12-22
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies
RecruitingCTIS2023-504984-17-00
Start: 2022-10-05Target: 176Updated: 2025-11-27
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
RecruitingNCT07181161
Start: 2025-10-01End: 2029-01-18Target: 283Updated: 2026-08-31
A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Metastatic Prostate Cancer.
Not yet recruitingCTIS2024-520026-11-00
Target: 107Updated: 2025-12-15